Acrolein: a respiratory toxin that suppresses pulmonary host defense

Reviews on Environmental Health

Volumn 13, Issue 1-2, 1998, Pages 99-108

  Li, Li ^a   Holian, Andrij ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

Acrolein; Alveolar macrophage; Immunosuppression; Respiratory tract

Indexed keywords

ACROLEIN;

AIR POLLUTION; CIGARETTE SMOKING; ENVIRONMENTAL EXPOSURE; EPITHELIUM CELL; EXHAUST GAS; HEALTH HAZARD; HOST RESISTANCE; HUMAN; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE FUNCTION; RESPIRATORY TRACT INJURY; REVIEW;

ACROLEIN; AIR POLLUTION; ENVIRONMENTAL EXPOSURE; EPITHELIAL CELLS; HUMANS; IMMUNE TOLERANCE; MACROPHAGES, ALVEOLAR; PUBLIC HEALTH; RESPIRATORY TRACT DISEASES;

ANIMALIA;

EID: 0031842243     PISSN: 00487554     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. WHO. Environmental health criteria 127: Acrolein. Geneva: International Program on Chemical Safety World Health Organization; 1992.
2. Caldwell JC, Woodruff TJ, Morello-Frosch R, Axelrad DA. Application of health information to hazardous air pollutants modeled in EPA's cumulative exposure project. Toxicol Ind Health 1998; 14: 429-454.
3. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for acrolein. In: ATSDR/TP-90-01; 1990.
4. Lipari F, Dasch JM, Scruggs WF. Aldehyde emissions from wood-burning fireplaces. Environ Sci Tech 1984; 18: 326-330.
5. Oberdorfer PE. The determination of aldehydes in automobile exhaust gas. In: Vehicle emissions: Society of Automotive Engineers Prog Tech, 1971; 32-42.
6. U.S. Environmental Protection Agency (EPA). Health Assessment document for acrolein: Washington, DC: EPA-600/8-86-014A, 1986.
7. World Health Organization (WHO). Environmental health criteria document acrolein. Geneva: International Program on Chemical Safety. WHO ISC/HSG/89.28, 1988.
8. Ghilarducci DP, Tjeerdema RS. Fate and effects of acrolein. Rev. Environ Contain Toxicol 1995; 144: 95-146.
9. Fischer T, Weber A, Grandjean E. Air pollution due to tobacco smoke in restaurants. Int Arch Occup Environ Health 1978; 41: 267-280.
10. Jermini C, Weber A, Grandjean E. Quantitative determination of various gas-phase components of the side-stream smoke of cigarettes in the room air as a contribution to the problem of passive-smoking. Int Arch Occup Environ Health 1976; 36: 169-181.
11. Turuk-Pchelina ZF. Acrolein releases into the air while cooking. Gig I Sanit 1960; 25: 96-9.
12. Protsenno GA, Trubilko VI, Savchenkov VA. Working conditions when metals to which primer has been applied are welded evaluated from the health and hygiene aspect. Avt. Svarka 1973; 2: 65-68.
13. Rietz B. Determination of the three aldehydes in the air of working environments. Anal Lett 1985; 18: 2369-2379.
14. Treitman RD, Burgess WA, Gold A. Air contaminants encountered by firefighters. Am Ind Hyg Assoc J 1980; 41: 796-802.
15. Alarcon RA. Studies on the in vivo formation of acrolein: 3-hydroxy-propylmercapturic acid as an index of cyclophosphamide (NSC-26271) activation. Cancer Treat Rep 1976; 60: 327-335.
16. RIVM. Update of the exploratory report acrolein. Bilthoven, The Netherlands: National Institute of Public Health and Environmental Protection; Report No.: 601014001, 1994.
17. Egle JL, Jr. Retention of inhaled formaldehyde, propionaldehyde, and acrolein in the dog. Arch Environ Health 1972; 25: 119-124.
18. Lam CW, Casanova M, Heck HD. Depletion of nasal mucosal glutathione by acrolein and enhancement of formaldehyde-induced DNA-protein cross-linking by simultaneous exposure to acrolein. Arch Toxicol 1985; 58: 67-71.
19. Beeley JM, Crow J, Jones JG, Minty B, Lynch RD, Pryce DP. Mortality and lung histopathology after inhalation lung injury. The effect of corticosteroids. Am Rev Respir Dis 1986; 133: 191-196.
20. Draminski W, Eder E, Henschler D. A new pathway of acrolein metabolism in rats. Arch Toxicol 1983; 52: 243-247.
21. Green GM, Jakab GJ, Low RB, Davis GS. Defense mechanisms of the respiratory membrane. Am Rev Respir Dis 1977; 115: 479-514.
22. Green GM. Mechanisms of tobacco smoke toxicity on pulmonary macrophage cells. Eur J Respir Dis Suppl 1985; 139: 82-85.
23. Jakab GJ. Adverse effect of a cigarette smoke component, acrolein, on pulmonary antibacterial defenses and on viral-bacterial interactions in the lung. Am Rev Respir Dis 1977; 115: 33-38.
24. Patel JM, Ortiz E, Kolmstetter C, Leibman KC. Selective inactivation of rat lung and liver microsomal NADPH-cytochrome c reductase by acrolein. Drug Metab Dispos 1984; 12: 460-463.
25. Patel JM, Block ER, Hood CI. Biochemical indices of cyclophosphamide-induced lung toxicity. Tox Appl Pharm 1984; 76: 128-138.
26. Gosselin B, Wattel F, Chopin C, Degand P, Fruchart JC, Van der Loo D, et al. A case of acute acrolein poisoning. Nouv Presse Med 1979; 8: 2469-2472.
27. Champeix J, Courtial L, Perche E, Catalina P. Acute broncho-pneumopathy from acrolein vapors. Arch Mal Prof 1966; 27: 794-796.
28. Weber-Tschopp A, Fischer T, Gierer R, Grandjean E. Experimental irritation by acrolein in human beings. Z Arbeitswiss 1977; 32: 166-171.
29. Ballantyne B, Dodd DE, Pritts IM, Nachreiner DJ, Fowler EH. Acute vapor inhalation toxicity of acrolein and its influence as a trace contaminant in 2-methoxy-3,4-dihydro-2H-pyran. Hum Toxicol 1989; 8: 229-235.
30. Carpenter CP, Smyth HFJ, Pozzani UC. The assay of acute vapor toxicity, and the grading and interpretation of results on 96 chemical compounds. J Ind Hyg Toxicol 1949; 31: 343-346.
31. Catilina P, Thieblot L, Champeix J. Experimental respiratory lesions by inhalation of acrolein in the rat Arch Mal Prof 1966; 27: 857-867.
32. Kruysse A. Acute inhalation toxicity of acrolein in hamster. Zeist, The Netherlands: Central Institute for Nutrition and Food Research, TNO R3516, 1971.
33. Philippin C, Gilgen A, Grandjean E. Toxicological and physiological investigation on acrolein inhalation in the mouse. Int Arch Arbeitsmed 1970; 26: 281-305.
34. Kane LE, Alarie Y. Sensory irritation to formaldehyde and acrolein during single and repeated exposures in mice. Am Ind Hyg Assoc J 1977; 38: 509-522.
35. Nielsen GD, Bakbo JC, Holst E. Sensory irritation and pulmonary irritation by airborne allyl acetate, allyl alcohol, and allyl ether compared to acrolein. Acta Pharmacol Toxicol (Copenhagen) 1984; 54: 292-298.
36. Steinhagen WH, Barrow CS. Sensory irritation structure-activity study of inhaled aldehydes in B6C3F1 and Swiss-Webster mice. Tox Appl Pharm 1984; 72: 495-503.
37. Leikauf GD, Leming LM, O'Donnell JR, Doupnik CA. Bronchial responsiveness and inflammation in guinea pigs exposed to acrolein. J Appl Physiol 1989; 66: 171-178.
38. Buckley LA, Jiang XZ, James RA, Morgan KT, Barrow CS. Respiratory tract lesions induced by sensory irritants at the RD50 concentration. Tox Appl Pharm 1984; 74: 417-429.
39. Hales CA, Barkin PW, Jung W, Trautman E, Lamborghini D, Herrig N, et al. Synthetic smoke with acrolein but not HCl produces pulmonary edema. J Appl Physiol 1988; 64: 1121-1133.
40. Feron VJ, Kruysse A, Til HP, Immel HR. Repeated exposure to acrolein vapor: subacute studies in hamsters, rats and rabbits. Toxicol 1978; 9: 47-57.
41. Kutzman RS, Wehner RW, Haber SB. Selected responses of hypertension-sensitive and resistant rats to inhaled acrolein. Toxicol 1984; 31: 53-65.
42. Kutzman RS, Popenoe EA, Schmaeler M, Drew RT. Changes in rat lung structure and composition as a result of subchronic exposure to acrolein. Toxicol 1985; 34: 139-151.
43. Leach CL, Hatoum NS, Ratajczak HV, Gerhart JM. The pathologic and immunologic effects of inhaled acrolein in rats. Toxicol Lett 1987; 39: 189-198.
44. Lyon JP, Jenkins LJ, Jr., Jones RA, Coon RA, Siegel J. Repeated and continuous exposure of laboratory animals to acrolein. Tox Appl Pharm 1970; 17: 726-732.
45. Le Bouffant L, Martin JC, Daniel H, Henin JP, Normand C. Action of intensive cigarette smoke inhalations on the rat lung. Role of particulate and gaseous cofactors. J Natl Cancer Inst 1980; 64: 273-284.
46. Higgins MW, Keller JB, Becker M, Howatt W, Landis JR, Rotman H, et al. An index of risk for obstructive airways disease. Am Rev Respir Dis 1982; 125: 144-151.
47. Higgins M. Epidemiology of COPD. State of the art. Chest 1984; 85: 3S-8S.
48. Nakamura Y, Romberger DJ, Tate L, Ertl RF, Kawamoto M, Adachi Y, et al. Cigarette smoke inhibits lung fibroblast proliferation and chemotaxis. Am J Respir Crit Care Med 1995; 151: 1497-1503.
49. Aranyi C, O'Shea WJ, Graham JA, Miller FJ. The effects of inhalation of organic chemical air contaminants on murine lung host defenses. Fund Appl Toxicol 1986; 6: 713-720.
50. Astry CL, Jakab GJ. The effects of acrolein exposure on pulmonary antibacterial defenses. Tox Appl Pharm 1983; 67: 49-54.
51. Bouley G, Dubreuil A, Godin J, Boudene C. Effects in the rat of a weak dose of acrolein inhaled continuously. Eur J Toxicol Environ Hyg 1975; 8: 291-297.
52. Sherwood RL, Leach CL, Hatoum NS, Aranyi C. Effects of acrolein on macrophage functions in rats. Toxicol Lett 1986; 32: 41-49.
53. Dahlgren SE, Dalen H, Dalhamm T. Ultrastructural observations on chemically induced inflammation in guinea pig trachea. Virchows Arch B Cell Pathol 1972; 11: 211-223.
54. Kilburn KH, McKenzie WN. Leukocyte recruitment to airways by aldehyde-carbon combinations that mimic cigarette smoke. Lab Invest 1978; 38: 134-142.
55. Fels AO, Cohn ZA. The alveolar macrophage. J Appl Physiol 1986; 60: 353-369.
56. Holian A. Inflammatory cells of the lung: Macrophages. In: Sipes IG, McQueen CA, Gandolfi AJ, eds, Comprehensive Toxicology. New York: Elsevier Science Inc., 1997; 115-131.
57. Cher DJ, Mosmann TR. Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones. J Immunol 1987; 138: 3688-3694.
58. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann Rev Immunol 1995; 13: 251-276.
59. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995; 80: 707-718.
60. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell co-stimulation. Ann Rev Immunol 1996; 14: 233-2358.
61. Gajewski TF, Schell SR, Nau G, Fitch FW. Regulation of T-cell activation: differences among T-cell subsets. Immunol Rev 1989; 111: 79-110.
62. Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Ann Rev Immunol 1994; 12: 635-673.
63. Grundfest CC, Chang J, Newcombe D. Acrolein: a potent modulator of lung macrophage arachidonic acid metabolism. Biochim Biophys Acta 1982; 713: 149-159.
64. Leffingwell CM, Low RB. Cigarette smoke components and alveolar macrophage protein synthesis. Arch Environ Health 1979; 34: 97-102.
65. Low ES, Low RB, Green GM. Correlated effects of cigarette smoke components on alveolar macrophage adenosine triphosphatase activity and phagocytosis. Am Rev Respir Dis 1977; 115: 963-970.
66. Li L, Hamilton RF, Jr., Taylor DE, Holian A. Acrolein-induced cell death in human alveolar macrophages. Tox Appl Pharm 1997; 145: 331-339.
67. Dinarello CA. Interleukin-1 and the effects of cyclooxygenase inhibitors on its biological activities. Bull N Y Acad Med 1989; 65: 80-92.
68. Nacy CA, Meierovics AI, Belosevic M, Green SJ. Tumor necrosis factor-alpha: central regulatory cytokine in the induction of macrophage antimicrobial activities. Pathobiol 1991; 59: 182-184.
69. Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. Apmis 1995; 103: 161-79.
70. Trinchieri G, Gerosa F. Immunoregulation by interleukin-12. J Leukoc Biol 1996; 59: 505-11.
71. Li L, Hamilton RF Jr, Holian A. Effect of acrolein on human alveolar macrophage NF-kappa B activity. Am J Physiol: Lung Cell Mol Physiol (Submitted).
72. Blackwell TS, Christman JW. The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol 1997; 17: 3-9.
73. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996; 274: 782-4.
74. Wang CY, Mayo MW, Baldwin AS, Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996; 274: 784-7.
75. Calabresi P, R. E. Parks J. The Pharmacologic Basis of Therapeutics. New York: MacMillan Co.; 1980.